CJC / Ipamorelin
Select Size
$49.99
A dual-peptide growth-hormone-secretagogue blend commonly used in research settings to evaluate complementary signaling through GHRH and ghrelin receptor pathways. CJC-type analog activity supports pituitary GHRH receptor stimulation while ipamorelin selectively targets GHSR-1a, enabling pulsatile GH-axis research with reduced off-target endocrine noise.
Certificate of Analysis
Third-party verified · HPLC & Mass Spectrometry
Purity
99.839%
Search Code
Alph2602150135
Test Date
Feb 17, 2026
Laboratory
Freedom Diagnostics
Compound Details
Mechanism of Action
CJC and ipamorelin engage distinct but convergent pathways in the GH axis: GHRH receptor stimulation increases cAMP-driven pituitary release signaling while GHSR-1a activation amplifies pulsatile GH output, supporting combination studies of endocrine rhythm and recovery-related signaling.
Molecular Profile
- Molecular Weight
- Blend: CJC analog and ipamorelin peptides in fixed-ratio lyophilized formulation
- Purity Spec
- >=98% by HPLC for each peptide component
Storage
Store lyophilized at -20C. Reconstituted: 2-8C, use within 21 days. Minimize agitation and avoid repeated freeze-thaw cycles.
Research Applications
Composition
What's in this blend — peptide by peptide.
Total blend: 10mg
CJC
5mgGHRH-pathway agonist analog used to study pituitary GH pulse initiation and downstream IGF-1 dynamics.
Ipamorelin
5mgSelective ghrelin receptor (GHSR-1a) agonist used to evaluate GH-release synergy with reduced prolactin and cortisol spillover.
Published Research
Peer-reviewed studies from PubMed.
Controlled human study of CJC-1295 showing sustained GH and IGF-1 elevation consistent with long-acting GHRH analog pharmacology.
- Demonstrated prolonged GH/IGF-1 axis stimulation in healthy adults
- Characterized long-acting exposure profile for CJC-1295
- Supports GHRH-analog component rationale in combination research
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog2007Endocrine Dynamics
Study reporting that CJC-1295 can enhance GH output while preserving pulsatile secretion architecture, relevant to physiologic-axis modeling.
- Observed preservation of pulsatile GH release pattern during stimulation
- Added physiologic context for sustained GHRH-analog signaling
- Informed pulse-pattern analyses in GH-axis research design
Foundational pharmacology paper describing ipamorelin as a selective growth hormone secretagogue with comparatively limited off-target pituitary hormone release.
- Established ipamorelin selectivity profile as a GHSR agonist
- Supported selective GH-axis stimulation model
- Provided mechanistic basis for pairing with GHRH-analog approaches
